Cargando…
An Observational Cross-Sectional Study of Gender and Disability as Determinants of Person-Centered Medicine in Botulinum Neurotoxin Treatment of Upper Motoneuron Syndrome
The motor behaviour of patients with Upper Motor Neuron Syndrome (UMNS) is characterised by spasticity. The first-line treatment for this clinical condition is Botulinum neurotoxin A (BoNTA), but the number and key locations of muscles which need to be treated is not much discussed in the literature...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024520/ https://www.ncbi.nlm.nih.gov/pubmed/35448855 http://dx.doi.org/10.3390/toxins14040246 |
_version_ | 1784690614059663360 |
---|---|
author | Del Prete, Cristina Maria Viva, Mattia Giuseppe De Trane, Stefania Brindisino, Fabrizio Barassi, Giovanni Specchia, Alessandro Di Iorio, Angelo Pellegrino, Raffaello |
author_facet | Del Prete, Cristina Maria Viva, Mattia Giuseppe De Trane, Stefania Brindisino, Fabrizio Barassi, Giovanni Specchia, Alessandro Di Iorio, Angelo Pellegrino, Raffaello |
author_sort | Del Prete, Cristina Maria |
collection | PubMed |
description | The motor behaviour of patients with Upper Motor Neuron Syndrome (UMNS) is characterised by spasticity. The first-line treatment for this clinical condition is Botulinum neurotoxin A (BoNTA), but the number and key locations of muscles which need to be treated is not much discussed in the literature. Cross-sectional analysis of outpatient cohort with UMNS spasticity, who were potential candidates for BoNTA treatment, was performed. Between November 2020 and November 2021, all consecutive adult patients eligible for BoNTA treatment were enrolled. The inclusion criteria encompass UMNS spasticity (onset being ≥6 months), with disabling muscles hypertonia. Patients underwent a clinical evaluation, a comprehensive assessment with the Modified Ashworth Scale, with the Modified Rankin Scale, and a patients’ perception-centred questionnaire. In total, 68 participants were enrolled in the study, among them 40 (58.8%) were male; mean age 57.9 ± 15.1. In women, BoNTA was more frequently required for adductor group muscles, independently from potential confounders (OR = 7.03, 95%CI: 1.90–25.97). According to the pattern of disability, patients with hemiparesis more frequently need to be treated in the upper limb, whereas the diplegia/double-hemiparesis group needed to be treated more frequently at the adductor and crux muscles compared to their counterparts. UMNS spasticity in women could require more attention to be paid to the treatment of adductor muscle spasticity, potentially because the dysfunction of those muscles could influence sphincteric management, required for perineal hygiene and/or sexual life. |
format | Online Article Text |
id | pubmed-9024520 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-90245202022-04-23 An Observational Cross-Sectional Study of Gender and Disability as Determinants of Person-Centered Medicine in Botulinum Neurotoxin Treatment of Upper Motoneuron Syndrome Del Prete, Cristina Maria Viva, Mattia Giuseppe De Trane, Stefania Brindisino, Fabrizio Barassi, Giovanni Specchia, Alessandro Di Iorio, Angelo Pellegrino, Raffaello Toxins (Basel) Article The motor behaviour of patients with Upper Motor Neuron Syndrome (UMNS) is characterised by spasticity. The first-line treatment for this clinical condition is Botulinum neurotoxin A (BoNTA), but the number and key locations of muscles which need to be treated is not much discussed in the literature. Cross-sectional analysis of outpatient cohort with UMNS spasticity, who were potential candidates for BoNTA treatment, was performed. Between November 2020 and November 2021, all consecutive adult patients eligible for BoNTA treatment were enrolled. The inclusion criteria encompass UMNS spasticity (onset being ≥6 months), with disabling muscles hypertonia. Patients underwent a clinical evaluation, a comprehensive assessment with the Modified Ashworth Scale, with the Modified Rankin Scale, and a patients’ perception-centred questionnaire. In total, 68 participants were enrolled in the study, among them 40 (58.8%) were male; mean age 57.9 ± 15.1. In women, BoNTA was more frequently required for adductor group muscles, independently from potential confounders (OR = 7.03, 95%CI: 1.90–25.97). According to the pattern of disability, patients with hemiparesis more frequently need to be treated in the upper limb, whereas the diplegia/double-hemiparesis group needed to be treated more frequently at the adductor and crux muscles compared to their counterparts. UMNS spasticity in women could require more attention to be paid to the treatment of adductor muscle spasticity, potentially because the dysfunction of those muscles could influence sphincteric management, required for perineal hygiene and/or sexual life. MDPI 2022-03-30 /pmc/articles/PMC9024520/ /pubmed/35448855 http://dx.doi.org/10.3390/toxins14040246 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Del Prete, Cristina Maria Viva, Mattia Giuseppe De Trane, Stefania Brindisino, Fabrizio Barassi, Giovanni Specchia, Alessandro Di Iorio, Angelo Pellegrino, Raffaello An Observational Cross-Sectional Study of Gender and Disability as Determinants of Person-Centered Medicine in Botulinum Neurotoxin Treatment of Upper Motoneuron Syndrome |
title | An Observational Cross-Sectional Study of Gender and Disability as Determinants of Person-Centered Medicine in Botulinum Neurotoxin Treatment of Upper Motoneuron Syndrome |
title_full | An Observational Cross-Sectional Study of Gender and Disability as Determinants of Person-Centered Medicine in Botulinum Neurotoxin Treatment of Upper Motoneuron Syndrome |
title_fullStr | An Observational Cross-Sectional Study of Gender and Disability as Determinants of Person-Centered Medicine in Botulinum Neurotoxin Treatment of Upper Motoneuron Syndrome |
title_full_unstemmed | An Observational Cross-Sectional Study of Gender and Disability as Determinants of Person-Centered Medicine in Botulinum Neurotoxin Treatment of Upper Motoneuron Syndrome |
title_short | An Observational Cross-Sectional Study of Gender and Disability as Determinants of Person-Centered Medicine in Botulinum Neurotoxin Treatment of Upper Motoneuron Syndrome |
title_sort | observational cross-sectional study of gender and disability as determinants of person-centered medicine in botulinum neurotoxin treatment of upper motoneuron syndrome |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024520/ https://www.ncbi.nlm.nih.gov/pubmed/35448855 http://dx.doi.org/10.3390/toxins14040246 |
work_keys_str_mv | AT delpretecristinamaria anobservationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT vivamattiagiuseppe anobservationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT detranestefania anobservationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT brindisinofabrizio anobservationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT barassigiovanni anobservationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT specchiaalessandro anobservationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT diiorioangelo anobservationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT pellegrinoraffaello anobservationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT delpretecristinamaria observationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT vivamattiagiuseppe observationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT detranestefania observationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT brindisinofabrizio observationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT barassigiovanni observationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT specchiaalessandro observationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT diiorioangelo observationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome AT pellegrinoraffaello observationalcrosssectionalstudyofgenderanddisabilityasdeterminantsofpersoncenteredmedicineinbotulinumneurotoxintreatmentofuppermotoneuronsyndrome |